PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33005285-1	2019	To investigate the dynamical properties of the novel hybrid compound, lithium benzimidazolate-borohydride Li2(bIm)BH4 (where bIm denotes a benzimidazolate anion, C7N2H5 -), we have used a set of complementary techniques: neutron powder diffraction, ab initio density functional theory calculations, neutron vibrational spectroscopy, nuclear magnetic resonance, neutron spin echo, and quasi-elastic neutron scattering.	bim	110-113	ATP binding cassette subfamily A member 12	Homo sapiens	106-109
28652304-6	2017	Bim deficiency rescued IELp development in RasGRP1-/- mice, suggesting that RasGRP1 functions to promote survival during IELp generation.	bim	0-3	RAS guanyl releasing protein 1	Mus musculus	43-50
29212192-0	2017	Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction.	bim	70-73	epidermal growth factor receptor	Homo sapiens	35-39
30187173-3	2018	In this study we investigated whether two peptide compounds, BIM-22776 (#776) and BIM-22A299 (#299), are effective MC2R antagonists in vitro.	bim	61-64	melanocortin 2 receptor	Canis lupus familiaris	115-119
30187173-3	2018	In this study we investigated whether two peptide compounds, BIM-22776 (#776) and BIM-22A299 (#299), are effective MC2R antagonists in vitro.	bim	82-85	melanocortin 2 receptor	Canis lupus familiaris	115-119
29774773-9	2018	Administration of miR-711 inhibitor elevates Ang-1 after TBI whereas Ang-1 administration increases Akt activation; reduces Puma, Noxa, Bim, and Bax levels; and attenuates caspase-dependent and -independent neuronal apoptosis 24 h after TBI.	bim	136-139	angiopoietin 1	Mus musculus	69-74
29278499-0	2018	BIM Binding Remotely Regulates BAX Activation: Insights from the Free Energy Landscapes.	bim	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	31-34
29051323-4	2018	Derepression of BIM expression by depletion of ZEB1 or treatment with the BH3 mimetic ABT-263 to enhance "free" cellular BIM levels both led to resensitization of mesenchymal EGFR-mutant cancers to EGFRi.	bim	16-19	zinc finger E-box binding homeobox 1	Homo sapiens	47-51
29051323-4	2018	Derepression of BIM expression by depletion of ZEB1 or treatment with the BH3 mimetic ABT-263 to enhance "free" cellular BIM levels both led to resensitization of mesenchymal EGFR-mutant cancers to EGFRi.	bim	16-19	epidermal growth factor receptor	Homo sapiens	175-179
28905400-8	2017	In vitro studies indicated that treatment with the BIM-23926 sst1 agonist, as well as SSTR1 overexpression, decreased, whereas SSTR1 silencing increased, cell-proliferation in 22Rv1 cells, likely through the regulation of PI3K/AKT-CCND3 signaling-pathway.	bim	51-54	AKT serine/threonine kinase 1	Homo sapiens	227-230
28905400-8	2017	In vitro studies indicated that treatment with the BIM-23926 sst1 agonist, as well as SSTR1 overexpression, decreased, whereas SSTR1 silencing increased, cell-proliferation in 22Rv1 cells, likely through the regulation of PI3K/AKT-CCND3 signaling-pathway.	bim	51-54	cyclin D3	Homo sapiens	231-236
28652304-6	2017	Bim deficiency rescued IELp development in RasGRP1-/- mice, suggesting that RasGRP1 functions to promote survival during IELp generation.	bim	0-3	RAS guanyl releasing protein 1	Mus musculus	76-83
27054332-0	2016	BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors.	bim	0-3	BCL2 apoptosis regulator	Homo sapiens	81-86
27890930-0	2017	Histone deacetylase inhibitors interrupt HSP90 RASGRP1 and HSP90 CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.	bim	97-100	heat shock protein 90 alpha family class A member 1	Homo sapiens	41-46
27890930-0	2017	Histone deacetylase inhibitors interrupt HSP90 RASGRP1 and HSP90 CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.	bim	97-100	RAS guanyl releasing protein 1	Homo sapiens	47-54
27890930-0	2017	Histone deacetylase inhibitors interrupt HSP90 RASGRP1 and HSP90 CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.	bim	97-100	heat shock protein 90 alpha family class A member 1	Homo sapiens	59-64
27890930-0	2017	Histone deacetylase inhibitors interrupt HSP90 RASGRP1 and HSP90 CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.	bim	97-100	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	65-69
27966610-8	2016	H547A displays a differential sensitivity to PMA- or BIM-induced activation or inhibition of DAT function relative to WT hDAT, indicating a change in basal PKC activity in H547A.	bim	53-56	solute carrier family 6 member 3	Homo sapiens	93-96
26578184-5	2016	BIM SAHB binding was shown to invoke the exposure of the 6A7 epitope (amino acids 13-19) and of the BH3 domain of BAX, followed by mobilization of the BAX [Formula: see text]-helix.	bim	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	114-117
26578184-5	2016	BIM SAHB binding was shown to invoke the exposure of the 6A7 epitope (amino acids 13-19) and of the BH3 domain of BAX, followed by mobilization of the BAX [Formula: see text]-helix.	bim	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	151-154
28493627-2	2017	Described herein is that the platinum (boryl)iminomethane (BIM) complex [Pt(kappa2 -N,B-Cy2 BIM)(CNArDipp2 )] can effect the oxidative insertion of a range of unsaturated organic substrates, including azides, isocyantes, and nitriles, as well as CO2 and elemental sulfur (S8 ).	bim	59-62	nudix hydrolase 4	Homo sapiens	97-106
27997540-16	2016	Both the MEK-ERK and AKT pathways also inactivate BIM, an essential molecule for steroid-induced cell death, and inhibit GSK3B, an important regulator of proapoptotic BIM.	bim	50-53	mitogen-activated protein kinase kinase 7	Homo sapiens	9-12
27997540-16	2016	Both the MEK-ERK and AKT pathways also inactivate BIM, an essential molecule for steroid-induced cell death, and inhibit GSK3B, an important regulator of proapoptotic BIM.	bim	50-53	mitogen-activated protein kinase 1	Homo sapiens	13-16
27997540-16	2016	Both the MEK-ERK and AKT pathways also inactivate BIM, an essential molecule for steroid-induced cell death, and inhibit GSK3B, an important regulator of proapoptotic BIM.	bim	50-53	AKT serine/threonine kinase 1	Homo sapiens	21-24
27826607-6	2016	In addition, the platinum (boryl)iminomethane (BIM) complex Pt(kappa2-N,B-Cy2BIM)(CNArDipp2) has illuminated a general ligand design strategy that can engender significant reverse-dative interactions with buttressed Lewis acids, and also has expanded the known scope of cooperative reactivity that can be realized at a transition metal-borane linkage.	bim	47-50	nudix hydrolase 4	Homo sapiens	82-91
27447985-3	2016	Here we report the discovery of a small molecule that efficiently blocks Bim-induced apoptosis after Bax is activated on the mitochondria.	bim	73-76	BCL2 associated X, apoptosis regulator	Homo sapiens	101-104
27054332-0	2016	BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors.	bim	0-3	mitogen-activated protein kinase kinase 7	Homo sapiens	91-94
26947081-6	2016	Thus, MCL-1 has a major role in lymphoma initiating pro-B cells to oppose BIM, which is upregulated in response to oncogenic stress.	bim	74-77	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	6-11
26967369-5	2016	Exposure of wild-type AtT-20 cells to the sst2- and sst5-selective agonists BIM-23120 and BIM-23268, respectively, promoted a pertussis toxin- and tertiapin-Q-sensitive reduction in fluorescent signal intensity, which is indicative of activation of G protein-coupled inwardly rectifying potassium (GIRK) channels.	bim	76-79	somatostatin receptor 2	Mus musculus	42-46
26967369-5	2016	Exposure of wild-type AtT-20 cells to the sst2- and sst5-selective agonists BIM-23120 and BIM-23268, respectively, promoted a pertussis toxin- and tertiapin-Q-sensitive reduction in fluorescent signal intensity, which is indicative of activation of G protein-coupled inwardly rectifying potassium (GIRK) channels.	bim	76-79	somatostatin receptor 5	Mus musculus	52-56
25915848-5	2016	Mechanistically, PXN-mediated extracellular signal-regulated kinases (ERK) activation is responsible for TKI resistance via decreased Bcl2-interacting mediator of cell death (BIM) and increased Mcl-1 expression due to modulating their protein stabilities by phosphorylation of BIM at serine 69 and Mcl-1 at threonine 163.	bim	175-178	paxillin	Homo sapiens	17-20
25915848-5	2016	Mechanistically, PXN-mediated extracellular signal-regulated kinases (ERK) activation is responsible for TKI resistance via decreased Bcl2-interacting mediator of cell death (BIM) and increased Mcl-1 expression due to modulating their protein stabilities by phosphorylation of BIM at serine 69 and Mcl-1 at threonine 163.	bim	175-178	mitogen-activated protein kinase 1	Homo sapiens	30-68
25915848-5	2016	Mechanistically, PXN-mediated extracellular signal-regulated kinases (ERK) activation is responsible for TKI resistance via decreased Bcl2-interacting mediator of cell death (BIM) and increased Mcl-1 expression due to modulating their protein stabilities by phosphorylation of BIM at serine 69 and Mcl-1 at threonine 163.	bim	175-178	mitogen-activated protein kinase 1	Homo sapiens	70-73
26575826-8	2016	Cell death induced by combined treatment is Noxa- and/or BIM-dependent in some cell lines but in others appears to be mediated by down-regulation of BCL-XL and release of BAK from BCL-XL and MCL-1.	bim	57-60	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	191-196
26418950-7	2015	Importantly, shRNA mediated downregulation of BIM in the malignant glioma cell lines LN-229 and U87MG led to an attenuated cleavage of caspase-9 and, consequently, reduced the level of apoptosis following TMZ and ACNU treatment.	bim	46-49	caspase 9	Homo sapiens	135-144
26639561-1	2015	BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI).	bim	0-3	epidermal growth factor receptor	Homo sapiens	68-72
26639561-10	2015	These data suggest that the combination of EGFR TKI with mTOR or PDE4 inhibitors could be adequate therapy for EGFR-mutant NSCLC patients with high pretreatment levels of BIM and mTOR.	bim	171-174	epidermal growth factor receptor	Homo sapiens	43-47
26639561-10	2015	These data suggest that the combination of EGFR TKI with mTOR or PDE4 inhibitors could be adequate therapy for EGFR-mutant NSCLC patients with high pretreatment levels of BIM and mTOR.	bim	171-174	mechanistic target of rapamycin kinase	Homo sapiens	57-61
26639561-10	2015	These data suggest that the combination of EGFR TKI with mTOR or PDE4 inhibitors could be adequate therapy for EGFR-mutant NSCLC patients with high pretreatment levels of BIM and mTOR.	bim	171-174	phosphodiesterase 4A	Homo sapiens	65-69
26639561-10	2015	These data suggest that the combination of EGFR TKI with mTOR or PDE4 inhibitors could be adequate therapy for EGFR-mutant NSCLC patients with high pretreatment levels of BIM and mTOR.	bim	171-174	epidermal growth factor receptor	Homo sapiens	111-115
26109645-0	2015	IL-6 and ICOS Antagonize Bim and Promote Regulatory T Cell Accrual with Age.	bim	25-28	interleukin 6	Mus musculus	0-4
26473951-0	2015	Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.	bim	64-67	cytochrome c, somatic	Homo sapiens	96-108
26109645-0	2015	IL-6 and ICOS Antagonize Bim and Promote Regulatory T Cell Accrual with Age.	bim	25-28	inducible T cell co-stimulator	Mus musculus	9-13
25036778-3	2014	Investigations into its mode of action reveal that BIM traps Galphaq in the empty pocket conformation by permitting GDP exit but interdicting GTP entry, a molecular mechanism not yet assigned to any other small molecule Galpha inhibitor to date.	bim	51-54	succinate-CoA ligase GDP/ADP-forming subunit alpha	Homo sapiens	61-67
25124553-0	2015	Bim controls IL-15 availability and limits engagement of multiple BH3-only proteins.	bim	0-3	interleukin 15	Mus musculus	13-18
25124553-7	2015	Decreased IL-15 availability in Bim-deficient mice facilitated the elimination of cells with less memory potential via the additional pro-apoptotic molecules Noxa and Puma.	bim	32-35	interleukin 15	Mus musculus	10-15
25393474-6	2014	This phenotype correlated with a reduced accumulation of BIM upon TCR crosslinking in CBAP-deficient thymocytes.	bim	57-60	T cell receptor alpha variable 6-3	Mus musculus	66-69
25393474-6	2014	This phenotype correlated with a reduced accumulation of BIM upon TCR crosslinking in CBAP-deficient thymocytes.	bim	57-60	transmembrane protein 102	Mus musculus	86-90
25176652-0	2014	BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues.	bim	0-3	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	31-34
25176652-6	2014	We find a common specific requirement for BIM during MYC-induced apoptosis in multiple settings, which does not extend to the p53-responsive BH3 family member PUMA, and find no evidence of a role for p19ARF during MYC-induced apoptosis in the tissues examined.	bim	42-45	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	53-56
24552990-7	2014	We conclude that downregulation of BIM represents a key survival signal downstream of oncogenic MYC and PI3K-AKT signaling in treatment-resistant T-ALL.	bim	35-38	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	96-99
24552990-7	2014	We conclude that downregulation of BIM represents a key survival signal downstream of oncogenic MYC and PI3K-AKT signaling in treatment-resistant T-ALL.	bim	35-38	AKT serine/threonine kinase 1	Homo sapiens	109-112
24850748-14	2014	Utilizing three-dimensional structures of F1L bound to host proapoptotic proteins, we generated variants of F1L that neutralize Bim and/or Bak.	bim	128-131	Hypothetical protein	Vaccinia virus	42-45
24850748-14	2014	Utilizing three-dimensional structures of F1L bound to host proapoptotic proteins, we generated variants of F1L that neutralize Bim and/or Bak.	bim	128-131	Hypothetical protein	Vaccinia virus	108-111
25737542-8	2015	We found that SCLCs were sensitized to ABT-263 via TORC1/2 inhibition, which led to reduced MCL-1 protein levels, thereby facilitating BIM-mediated apoptosis.	bim	135-138	CREB regulated transcription coactivator 1	Homo sapiens	51-58
25124553-7	2015	Decreased IL-15 availability in Bim-deficient mice facilitated the elimination of cells with less memory potential via the additional pro-apoptotic molecules Noxa and Puma.	bim	32-35	phorbol-12-myristate-13-acetate-induced protein 1	Mus musculus	158-162
25049077-8	2014	At the cellular level, ghrelin induced a significant increase in action-potential firing, and blockade of GHS-R1a by BIM-28163 abolished the ghrelin-induced hyperexcitability.	bim	117-120	ghrelin and obestatin prepropeptide	Rattus norvegicus	141-148
24211300-3	2014	A 48-h treatment with BIM-23244 (SS2R/SS5R) or BIM-23926 (SS1R) SST analogs was more effective in inhibiting cell proliferation, compared to BIM-23120 (SS2R), BIM-23206 (SS5R) and BIM-23704 (SS1R/SS2R).	bim	22-25	somatostatin receptor 2	Homo sapiens	33-37
24966929-0	2014	Reduced miR-9 and miR-181a expression down-regulates Bim concentration and promote osteoclasts survival.	bim	53-56	microRNA 181a-2	Mus musculus	18-26
24634493-3	2014	In vitro IL-15 withdrawal showed that uneducated NK cells upregulated Bim and Fas.	bim	70-73	interleukin 15	Homo sapiens	9-14
24211300-3	2014	A 48-h treatment with BIM-23244 (SS2R/SS5R) or BIM-23926 (SS1R) SST analogs was more effective in inhibiting cell proliferation, compared to BIM-23120 (SS2R), BIM-23206 (SS5R) and BIM-23704 (SS1R/SS2R).	bim	22-25	somatostatin receptor 5	Homo sapiens	38-42
24211300-3	2014	A 48-h treatment with BIM-23244 (SS2R/SS5R) or BIM-23926 (SS1R) SST analogs was more effective in inhibiting cell proliferation, compared to BIM-23120 (SS2R), BIM-23206 (SS5R) and BIM-23704 (SS1R/SS2R).	bim	22-25	somatostatin receptor 5	Homo sapiens	170-174
24211300-3	2014	A 48-h treatment with BIM-23244 (SS2R/SS5R) or BIM-23926 (SS1R) SST analogs was more effective in inhibiting cell proliferation, compared to BIM-23120 (SS2R), BIM-23206 (SS5R) and BIM-23704 (SS1R/SS2R).	bim	22-25	somatostatin receptor 1	Homo sapiens	191-195
24211300-3	2014	A 48-h treatment with BIM-23244 (SS2R/SS5R) or BIM-23926 (SS1R) SST analogs was more effective in inhibiting cell proliferation, compared to BIM-23120 (SS2R), BIM-23206 (SS5R) and BIM-23704 (SS1R/SS2R).	bim	47-50	somatostatin receptor 1	Homo sapiens	58-62
24211300-3	2014	A 48-h treatment with BIM-23244 (SS2R/SS5R) or BIM-23926 (SS1R) SST analogs was more effective in inhibiting cell proliferation, compared to BIM-23120 (SS2R), BIM-23206 (SS5R) and BIM-23704 (SS1R/SS2R).	bim	47-50	somatostatin receptor 5	Homo sapiens	170-174
24211300-3	2014	A 48-h treatment with BIM-23244 (SS2R/SS5R) or BIM-23926 (SS1R) SST analogs was more effective in inhibiting cell proliferation, compared to BIM-23120 (SS2R), BIM-23206 (SS5R) and BIM-23704 (SS1R/SS2R).	bim	47-50	somatostatin receptor 1	Homo sapiens	191-195
24211300-5	2014	BIM-23244 (SS2R/SS5R) led to p21 increment only in PC-3 cells, and to pERK1/2 reduction in both cell lines.	bim	0-3	somatostatin receptor 2	Homo sapiens	11-15
24211300-5	2014	BIM-23244 (SS2R/SS5R) led to p21 increment only in PC-3 cells, and to pERK1/2 reduction in both cell lines.	bim	0-3	somatostatin receptor 5	Homo sapiens	16-20
24211300-5	2014	BIM-23244 (SS2R/SS5R) led to p21 increment only in PC-3 cells, and to pERK1/2 reduction in both cell lines.	bim	0-3	H3 histone pseudogene 16	Homo sapiens	29-32
23933517-5	2013	GF starvation increased levels of Bim in both model systems, which was prevented by RAF in 32D cells but not in NIH 3T3 fibroblasts.	bim	34-37	zinc fingers and homeoboxes 2	Mus musculus	84-87
23827939-4	2013	Tamiflu, specific MMP-9 inhibitor, neuromedin B receptor specific antagonist BIM23127, and the selective inhibitor of whole heterotrimeric G-protein complex BIM-46174 significantly block nucleic acid-induced TLR-7 and -9 MyD88 recruitment, NF-kappaB activation and proinflammatory TNFalpha and MCP-1 cytokine responses.	bim	77-80	toll like receptor 7	Homo sapiens	208-226
24025506-8	2013	CONCLUSION: In human basal-like breast cancer cell line HCC1937, p21(waf1) exerts anti-apoptotic activity by inhibiting the expression of bim, a mediator of mitochondrial apoptosis.	bim	138-141	cyclin dependent kinase inhibitor 1A	Homo sapiens	65-68
23732520-6	2013	Our studies delineate the signaling pathway controlling Bim upregulation, which results in Bax/Bak-independent apoptosis and provide evidence that the compounds can act as anticancer agents based on mammalian TrxRs inhibition.	bim	56-59	BCL2 associated X, apoptosis regulator	Homo sapiens	91-94
23732520-6	2013	Our studies delineate the signaling pathway controlling Bim upregulation, which results in Bax/Bak-independent apoptosis and provide evidence that the compounds can act as anticancer agents based on mammalian TrxRs inhibition.	bim	56-59	BCL2 antagonist/killer 1	Homo sapiens	95-98
23538902-6	2013	The critical role of increased BIM and decreased Mcl-1 expression in the survival of NRAS-mutant melanoma cell lines was shown through siRNA knockdown and overexpression studies.	bim	31-34	NRAS proto-oncogene, GTPase	Homo sapiens	85-89
23382048-2	2013	BIM upregulation is required for apoptosis induction by EGF receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) in EGFR-mutant forms of non-small cell lung cancer (NSCLC).	bim	0-3	epidermal growth factor receptor	Homo sapiens	56-68
23382048-2	2013	BIM upregulation is required for apoptosis induction by EGF receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) in EGFR-mutant forms of non-small cell lung cancer (NSCLC).	bim	0-3	epidermal growth factor receptor	Homo sapiens	70-74
23382048-2	2013	BIM upregulation is required for apoptosis induction by EGF receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) in EGFR-mutant forms of non-small cell lung cancer (NSCLC).	bim	0-3	epidermal growth factor receptor	Homo sapiens	104-108
23382048-2	2013	BIM upregulation is required for apoptosis induction by EGF receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) in EGFR-mutant forms of non-small cell lung cancer (NSCLC).	bim	0-3	epidermal growth factor receptor	Homo sapiens	104-108
22987245-0	2013	Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model.	bim	37-40	myostatin	Rattus norvegicus	83-92
23515849-6	2013	BIM-28163 antagonized ghrelin-induced GH secretion but not ghrelin-induced food consumption and cFos activation, rather it stimulated food intake and cFos activity without affecting GH secretion.	bim	0-3	ghrelin	Mus musculus	22-29
23515849-6	2013	BIM-28163 antagonized ghrelin-induced GH secretion but not ghrelin-induced food consumption and cFos activation, rather it stimulated food intake and cFos activity without affecting GH secretion.	bim	0-3	growth hormone	Mus musculus	38-40
23515849-7	2013	The level of cFos activation was dependent on the region considered: BIM-28163 was as active as ghrelin in the NTS, but less active in the ArcN and AP.	bim	69-72	FBJ osteosarcoma oncogene	Mus musculus	13-17
23515849-9	2013	In conclusion, these data demonstrate that two peptide analogs of ghrelin, BIM-28163, and BIM-28131, are powerful stimulators of appetite in mice, acting through pathways and key brain regions involved in the control of appetite that are only partially superimposable from those activated by ghrelin.	bim	75-78	ghrelin	Mus musculus	66-73
23515849-9	2013	In conclusion, these data demonstrate that two peptide analogs of ghrelin, BIM-28163, and BIM-28131, are powerful stimulators of appetite in mice, acting through pathways and key brain regions involved in the control of appetite that are only partially superimposable from those activated by ghrelin.	bim	75-78	ghrelin	Mus musculus	292-299
23515849-9	2013	In conclusion, these data demonstrate that two peptide analogs of ghrelin, BIM-28163, and BIM-28131, are powerful stimulators of appetite in mice, acting through pathways and key brain regions involved in the control of appetite that are only partially superimposable from those activated by ghrelin.	bim	90-93	ghrelin	Mus musculus	292-299
22987245-0	2013	Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model.	bim	51-54	myostatin	Rattus norvegicus	83-92
22987245-3	2013	Ghrelin and its analogues BIM-28125 and BIM-28131 (now known as RM-131) have been shown to increase weight in a rat model of CHF.	bim	26-29	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
22987245-3	2013	Ghrelin and its analogues BIM-28125 and BIM-28131 (now known as RM-131) have been shown to increase weight in a rat model of CHF.	bim	40-43	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
22987245-11	2013	The application of ghrelin analogue BIM-28125 and BIM-28131 in their higher concentrations led to a significant reduction in myostatin mRNA expression in comparison to placebo.	bim	36-39	myostatin	Rattus norvegicus	125-134
22987245-11	2013	The application of ghrelin analogue BIM-28125 and BIM-28131 in their higher concentrations led to a significant reduction in myostatin mRNA expression in comparison to placebo.	bim	50-53	myostatin	Rattus norvegicus	125-134
22987245-12	2013	Myostatin protein expression was significantly reduced in both concentrations of ghrelin and BIM-28131 and in the lower concentration of BIM-28125.	bim	93-96	myostatin	Rattus norvegicus	0-9
22987245-12	2013	Myostatin protein expression was significantly reduced in both concentrations of ghrelin and BIM-28131 and in the lower concentration of BIM-28125.	bim	137-140	myostatin	Rattus norvegicus	0-9
22987245-14	2013	CONCLUSIONS: In an animal model of CHF, the expression of myostatin is significantly reduced in the skeletal muscle after application of ghrelin and most concentrations of its analogues BIM-28125 and BIM-28131 possibly due to anti-inflammatory effects.	bim	186-189	myostatin	Rattus norvegicus	58-67
22987245-14	2013	CONCLUSIONS: In an animal model of CHF, the expression of myostatin is significantly reduced in the skeletal muscle after application of ghrelin and most concentrations of its analogues BIM-28125 and BIM-28131 possibly due to anti-inflammatory effects.	bim	200-203	myostatin	Rattus norvegicus	58-67
23797089-5	2013	Consistent with their antitumor response to BIM-23A758, GOT1 cells showed relatively high expression levels of SSTR2 and D2R mRNA.	bim	44-47	glutamic-oxaloacetic transaminase 1	Homo sapiens	56-60
23797089-5	2013	Consistent with their antitumor response to BIM-23A758, GOT1 cells showed relatively high expression levels of SSTR2 and D2R mRNA.	bim	44-47	somatostatin receptor 2	Homo sapiens	111-116
23797089-5	2013	Consistent with their antitumor response to BIM-23A758, GOT1 cells showed relatively high expression levels of SSTR2 and D2R mRNA.	bim	44-47	dopamine receptor D2	Homo sapiens	121-124
23516608-11	2013	Together, these results suggest that GILZ suppresses FOXO1 nuclear translocation, promotes SSC differentiation over self-renewal, and favours germ cell survival through inhibition of BIM-dependent pro-apoptotic signals.	bim	183-186	TSC22 domain family, member 3	Mus musculus	37-41
21360567-8	2011	CONCLUSION: CTLA-4 is expressed by HBV-specific CD8 T cells with high levels of Bim and helps to drive this proapoptotic phenotype.	bim	80-83	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	12-18
22968128-7	2012	Further, both D-amino acid oxygenase (DAAO), a degrading enzyme of D-serine, and bisindolylmaleimide alpha (BIM), a PKC inhibitor, attenuated morphine tolerance.	bim	108-111	protein kinase C, gamma	Rattus norvegicus	116-119
22349704-9	2012	The combined data clearly demonstrate that FOXO3 activates overproduction of ROS as a consequence of Bim-dependent impairment of mitochondrial respiration in neuronal cells, which leads to apoptosis.	bim	101-104	forkhead box O3	Homo sapiens	43-48
21478148-8	2011	Blocking p42/p44 MAPK activation following preconditioning ischemia with U0126 or using the nonphosphorylatable 3ABim reduced the binding between Bim and TRIM2.	bim	114-117	erythrocyte membrane protein band 4.2	Mus musculus	9-12
21478148-8	2011	Blocking p42/p44 MAPK activation following preconditioning ischemia with U0126 or using the nonphosphorylatable 3ABim reduced the binding between Bim and TRIM2.	bim	114-117	mitogen-activated protein kinase 3	Mus musculus	13-16
21478148-8	2011	Blocking p42/p44 MAPK activation following preconditioning ischemia with U0126 or using the nonphosphorylatable 3ABim reduced the binding between Bim and TRIM2.	bim	114-117	mitogen-activated protein kinase 3	Mus musculus	17-21
21478148-8	2011	Blocking p42/p44 MAPK activation following preconditioning ischemia with U0126 or using the nonphosphorylatable 3ABim reduced the binding between Bim and TRIM2.	bim	114-117	tripartite motif-containing 2	Mus musculus	154-159
21360567-8	2011	CONCLUSION: CTLA-4 is expressed by HBV-specific CD8 T cells with high levels of Bim and helps to drive this proapoptotic phenotype.	bim	80-83	CD8a molecule	Homo sapiens	48-51
21075822-8	2011	Pre-incubation with BIM blocked EGF-induced ERK 1/2 activation and Pit-1 expression.	bim	20-23	epidermal growth factor	Rattus norvegicus	32-35
21075822-8	2011	Pre-incubation with BIM blocked EGF-induced ERK 1/2 activation and Pit-1 expression.	bim	20-23	mitogen activated protein kinase 3	Rattus norvegicus	44-51
21075822-8	2011	Pre-incubation with BIM blocked EGF-induced ERK 1/2 activation and Pit-1 expression.	bim	20-23	POU class 1 homeobox 1	Rattus norvegicus	67-72
21114599-8	2011	Compared with hGLP-1(7-36)NH2, BIM-51077 had similar binding affinity for the human GLP-1 receptor and activated this receptor with similar potency.	bim	31-34	glucagon like peptide 1 receptor	Homo sapiens	84-98
22102869-0	2011	Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model.	bim	27-30	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
22102869-0	2011	Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model.	bim	27-30	tripartite motif containing 63	Rattus norvegicus	103-109
22102869-0	2011	Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model.	bim	27-30	F-box protein 32	Rattus norvegicus	114-119
22102869-0	2011	Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model.	bim	41-44	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
22102869-0	2011	Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model.	bim	41-44	tripartite motif containing 63	Rattus norvegicus	103-109
22102869-0	2011	Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model.	bim	41-44	F-box protein 32	Rattus norvegicus	114-119
21037099-2	2010	We have found that eliminating Bim-dependent apoptosis in IL-2- and CD25-deficient mice restored Treg numbers but failed to cure their lethal autoimmune disease, demonstrating that IL-2-dependent survival and suppressive activity can be uncoupled in Tregs.	bim	31-34	interleukin 2	Mus musculus	58-62
21203485-5	2010	As current small organic antagonists of Bcl-2 do not target BHRF1, the structures of it in complex with Bim or Bak shown here will be useful to guide efforts to target BHRF1 in EBV-associated malignancies, which are usually associated with poor clinical outcomes.	bim	104-107	BCL2 apoptosis regulator	Homo sapiens	40-45
21203485-5	2010	As current small organic antagonists of Bcl-2 do not target BHRF1, the structures of it in complex with Bim or Bak shown here will be useful to guide efforts to target BHRF1 in EBV-associated malignancies, which are usually associated with poor clinical outcomes.	bim	104-107	apoptosis regulator BHRF1	Human gammaherpesvirus 4	168-173
21086135-7	2010	In addition, in cells induced to differentiate by ATRA or VD3, Nitroblue-tetrazolium (NBT) reduction and esterase activity, were blocked either by LY294002, a PI3K inhibitor, or by BIM, a PKC inhibitor, without affecting cell surface markers such as CD11b or CD14.	bim	181-184	protein kinase C alpha	Homo sapiens	188-191
21086135-7	2010	In addition, in cells induced to differentiate by ATRA or VD3, Nitroblue-tetrazolium (NBT) reduction and esterase activity, were blocked either by LY294002, a PI3K inhibitor, or by BIM, a PKC inhibitor, without affecting cell surface markers such as CD11b or CD14.	bim	181-184	integrin subunit alpha M	Homo sapiens	250-255
21086135-7	2010	In addition, in cells induced to differentiate by ATRA or VD3, Nitroblue-tetrazolium (NBT) reduction and esterase activity, were blocked either by LY294002, a PI3K inhibitor, or by BIM, a PKC inhibitor, without affecting cell surface markers such as CD11b or CD14.	bim	181-184	CD14 molecule	Homo sapiens	259-263
20876239-6	2010	BIM-23244 (sstr2-sstr5 selective agonist) significantly increased the co-immunoprecipitation of sstr2/sstr5, and induced a -41.36% inhibition of proliferation.	bim	0-3	somatostatin receptor 2	Homo sapiens	11-16
20876239-6	2010	BIM-23244 (sstr2-sstr5 selective agonist) significantly increased the co-immunoprecipitation of sstr2/sstr5, and induced a -41.36% inhibition of proliferation.	bim	0-3	somatostatin receptor 5	Homo sapiens	17-22
20876239-6	2010	BIM-23244 (sstr2-sstr5 selective agonist) significantly increased the co-immunoprecipitation of sstr2/sstr5, and induced a -41.36% inhibition of proliferation.	bim	0-3	somatostatin receptor 2	Homo sapiens	96-101
20876239-6	2010	BIM-23244 (sstr2-sstr5 selective agonist) significantly increased the co-immunoprecipitation of sstr2/sstr5, and induced a -41.36% inhibition of proliferation.	bim	0-3	somatostatin receptor 5	Homo sapiens	102-107
21037099-2	2010	We have found that eliminating Bim-dependent apoptosis in IL-2- and CD25-deficient mice restored Treg numbers but failed to cure their lethal autoimmune disease, demonstrating that IL-2-dependent survival and suppressive activity can be uncoupled in Tregs.	bim	31-34	interleukin 2 receptor, alpha chain	Mus musculus	68-72
21037099-2	2010	We have found that eliminating Bim-dependent apoptosis in IL-2- and CD25-deficient mice restored Treg numbers but failed to cure their lethal autoimmune disease, demonstrating that IL-2-dependent survival and suppressive activity can be uncoupled in Tregs.	bim	31-34	interleukin 2	Mus musculus	181-185
19801996-7	2009	Furthermore, in order to study the signaling pathways of the I(KATP) augmented by hypoxia and the redox agent, we applied a protein kinase C(PKC) inhibitor bisindolylmaleimide VI (BIM), a protein kinase G(PKG) inhibitor KT5823, a protein kinase A (PKA) inhibitor H-89, and Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitors KN-62 and KN-93.	bim	180-183	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	230-246
20558134-8	2010	This increase was prevented by prior incubation with the PKC inhibitor bisindolymaleimide (BIM; 2 microM for 1 h; 0.10+/-0.01; n=3).	bim	91-94	proline rich transmembrane protein 2	Homo sapiens	57-60
19619936-4	2010	Moreover, BIM-23A760 and BIM-53097 induced ERK1/2 and p38 phosphorylation and the blockade of these pathways prevented both the antiproliferative and the pro-apoptotic effects of these drugs.	bim	10-13	mitogen-activated protein kinase 3	Homo sapiens	43-49
19619936-4	2010	Moreover, BIM-23A760 and BIM-53097 induced ERK1/2 and p38 phosphorylation and the blockade of these pathways prevented both the antiproliferative and the pro-apoptotic effects of these drugs.	bim	10-13	mitogen-activated protein kinase 1	Homo sapiens	54-57
19619936-4	2010	Moreover, BIM-23A760 and BIM-53097 induced ERK1/2 and p38 phosphorylation and the blockade of these pathways prevented both the antiproliferative and the pro-apoptotic effects of these drugs.	bim	25-28	mitogen-activated protein kinase 3	Homo sapiens	43-49
19619936-4	2010	Moreover, BIM-23A760 and BIM-53097 induced ERK1/2 and p38 phosphorylation and the blockade of these pathways prevented both the antiproliferative and the pro-apoptotic effects of these drugs.	bim	25-28	mitogen-activated protein kinase 1	Homo sapiens	54-57
20089895-5	2010	In wild-type, but not in sst2 knock-out mice, gamma oscillation power decreased lastingly after intrabulbar injection of an sst2-selective antagonist (BIM-23627), while sst2-selective agonists (octreotide and L-779976) durably increased it.	bim	151-154	somatostatin receptor 2	Mus musculus	124-128
20089895-5	2010	In wild-type, but not in sst2 knock-out mice, gamma oscillation power decreased lastingly after intrabulbar injection of an sst2-selective antagonist (BIM-23627), while sst2-selective agonists (octreotide and L-779976) durably increased it.	bim	151-154	somatostatin receptor 2	Mus musculus	124-128
19801996-7	2009	Furthermore, in order to study the signaling pathways of the I(KATP) augmented by hypoxia and the redox agent, we applied a protein kinase C(PKC) inhibitor bisindolylmaleimide VI (BIM), a protein kinase G(PKG) inhibitor KT5823, a protein kinase A (PKA) inhibitor H-89, and Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitors KN-62 and KN-93.	bim	180-183	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	248-251
18759927-9	2008	Bim, a pro-apoptotic Bcl-2 family member, exerts a positive regulatory effect on cell cycle entry, which is opposed by Bcl-2.	bim	0-3	BCL2 apoptosis regulator	Homo sapiens	21-26
19773433-6	2009	Results indicate that inhibition of the MAPK/ERK kinase (MEK)/ERK pathway in HepG2 cells, which are refractory to the proapoptotic effects of TGF-beta, sensitizes them to cell death through a mitochondrial-dependent mechanism, coincident with increased levels of BIM and BMF, decreased levels of BCL-XL and MCL1, and BAX/BAK activation.	bim	263-266	mitogen-activated protein kinase 1	Homo sapiens	40-44
19773433-6	2009	Results indicate that inhibition of the MAPK/ERK kinase (MEK)/ERK pathway in HepG2 cells, which are refractory to the proapoptotic effects of TGF-beta, sensitizes them to cell death through a mitochondrial-dependent mechanism, coincident with increased levels of BIM and BMF, decreased levels of BCL-XL and MCL1, and BAX/BAK activation.	bim	263-266	mitogen-activated protein kinase 1	Homo sapiens	45-48
19773433-6	2009	Results indicate that inhibition of the MAPK/ERK kinase (MEK)/ERK pathway in HepG2 cells, which are refractory to the proapoptotic effects of TGF-beta, sensitizes them to cell death through a mitochondrial-dependent mechanism, coincident with increased levels of BIM and BMF, decreased levels of BCL-XL and MCL1, and BAX/BAK activation.	bim	263-266	mitogen-activated protein kinase kinase 7	Homo sapiens	57-60
19773433-6	2009	Results indicate that inhibition of the MAPK/ERK kinase (MEK)/ERK pathway in HepG2 cells, which are refractory to the proapoptotic effects of TGF-beta, sensitizes them to cell death through a mitochondrial-dependent mechanism, coincident with increased levels of BIM and BMF, decreased levels of BCL-XL and MCL1, and BAX/BAK activation.	bim	263-266	mitogen-activated protein kinase 1	Homo sapiens	62-65
19129400-8	2009	Iron and BIM (Bcl-2-interacting mediator of cell death) proteins were involved in the cytotoxic sensitization process.	bim	9-12	Bcl2-like 11	Rattus norvegicus	14-54
18806830-5	2008	BIM is de-phosphorylated and upregulated following MEK1/2 inhibition in all CRC cell lines studied and knockdown of BIM reduces cell death, indicating that repression of BIM is a major part of the ability of BRAF(V600E) to confer growth factor-independent survival.	bim	0-3	mitogen-activated protein kinase kinase 1	Homo sapiens	51-57
18806830-5	2008	BIM is de-phosphorylated and upregulated following MEK1/2 inhibition in all CRC cell lines studied and knockdown of BIM reduces cell death, indicating that repression of BIM is a major part of the ability of BRAF(V600E) to confer growth factor-independent survival.	bim	0-3	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	208-213
18759927-9	2008	Bim, a pro-apoptotic Bcl-2 family member, exerts a positive regulatory effect on cell cycle entry, which is opposed by Bcl-2.	bim	0-3	BCL2 apoptosis regulator	Homo sapiens	119-124
18426817-10	2008	The SSTR5 compound, BIM-23206, produced a dose-dependent inhibition of PRL release similar to that of cabergoline in three DA-sensitive prolactinomas.	bim	20-23	somatostatin receptor 5	Homo sapiens	4-9
18523273-8	2008	TRAF1-deficient CD8 T cells fail to activate ERK in response to 4-1BB ligation and inhibition of ERK signaling downstream of 4-1BB in wild-type cells leads to increased Bim levels.	bim	169-172	mitogen-activated protein kinase 1	Homo sapiens	97-100
18523273-8	2008	TRAF1-deficient CD8 T cells fail to activate ERK in response to 4-1BB ligation and inhibition of ERK signaling downstream of 4-1BB in wild-type cells leads to increased Bim levels.	bim	169-172	TNF receptor superfamily member 9	Homo sapiens	125-130
18426817-10	2008	The SSTR5 compound, BIM-23206, produced a dose-dependent inhibition of PRL release similar to that of cabergoline in three DA-sensitive prolactinomas.	bim	20-23	prolactin	Homo sapiens	71-74
18426817-13	2008	Cabergoline and BIM-23A760 produced a partial inhibition of PRL secretion (19+/-6 and 21+/-3% respectively).	bim	16-19	prolactin	Homo sapiens	60-63
18039782-4	2008	Treatment with ghrelin and two ghrelin receptor agonists (BIM-28125 and BIM-28131) resulted in increased food intake and an improvement in lean body mass accrual that was related in part to a decrease in muscle protein degradation as assessed by muscle levels of the 14-kDa actin fragment resulting from cleaved actomyosin.	bim	58-61	ghrelin and obestatin prepropeptide	Rattus norvegicus	15-22
18195012-0	2008	BIM and tBID are not mechanistically equivalent when assisting BAX to permeabilize bilayer membranes.	bim	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	63-66
18195012-1	2008	BIM and tBID are two BCL-2 homology 3 (BH3)-only proteins with a particularly strong capacity to trigger BAX-driven mitochondrial outer membrane permeabilization, a crucial event in mammalian apoptosis.	bim	0-3	BCL2 apoptosis regulator	Homo sapiens	21-26
18195012-1	2008	BIM and tBID are two BCL-2 homology 3 (BH3)-only proteins with a particularly strong capacity to trigger BAX-driven mitochondrial outer membrane permeabilization, a crucial event in mammalian apoptosis.	bim	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	105-108
18195012-8	2008	Together, these results support the notion that BIM and tBID follow different strategies to trigger BAX-driven mitochondrial outer membrane permeabilization with strong potency.	bim	48-51	BCL2 associated X, apoptosis regulator	Homo sapiens	100-103
18289621-8	2008	The pre-treatment with PKC inhibitor BIM significantly inhibited the ERK activation promoted by insulin without modifying the ERK expression levels induced by estradiol or estradiol-BSA.	bim	37-40	mitogen-activated protein kinase 3	Homo sapiens	69-72
18289621-8	2008	The pre-treatment with PKC inhibitor BIM significantly inhibited the ERK activation promoted by insulin without modifying the ERK expression levels induced by estradiol or estradiol-BSA.	bim	37-40	insulin	Homo sapiens	96-103
18039782-4	2008	Treatment with ghrelin and two ghrelin receptor agonists (BIM-28125 and BIM-28131) resulted in increased food intake and an improvement in lean body mass accrual that was related in part to a decrease in muscle protein degradation as assessed by muscle levels of the 14-kDa actin fragment resulting from cleaved actomyosin.	bim	58-61	ghrelin and obestatin prepropeptide	Rattus norvegicus	31-38
18039782-4	2008	Treatment with ghrelin and two ghrelin receptor agonists (BIM-28125 and BIM-28131) resulted in increased food intake and an improvement in lean body mass accrual that was related in part to a decrease in muscle protein degradation as assessed by muscle levels of the 14-kDa actin fragment resulting from cleaved actomyosin.	bim	72-75	ghrelin and obestatin prepropeptide	Rattus norvegicus	15-22
18039782-4	2008	Treatment with ghrelin and two ghrelin receptor agonists (BIM-28125 and BIM-28131) resulted in increased food intake and an improvement in lean body mass accrual that was related in part to a decrease in muscle protein degradation as assessed by muscle levels of the 14-kDa actin fragment resulting from cleaved actomyosin.	bim	72-75	ghrelin and obestatin prepropeptide	Rattus norvegicus	31-38
18046413-6	2007	Analysis of mice deficient in both Bim (which is required for negative selection) and calcineurin revealed that calcineurin-induced ERK (extracellular signal-regulated kinase) sensitization is required for differentiation in response to "weak" positive selecting signals but not in response to "strong" negative selecting signals (which normally induce apoptosis).	bim	35-38	mitogen-activated protein kinase 1	Mus musculus	132-135
17522976-8	2008	The PKC inhibitor BIM (bisindolymaleimide-I) blocked the phosphorylation of ERK1/2 and activation of PKC induced by 12-LOX.	bim	18-21	proline rich transmembrane protein 2	Homo sapiens	4-7
17522976-8	2008	The PKC inhibitor BIM (bisindolymaleimide-I) blocked the phosphorylation of ERK1/2 and activation of PKC induced by 12-LOX.	bim	18-21	mitogen-activated protein kinase 3	Homo sapiens	76-82
17522976-8	2008	The PKC inhibitor BIM (bisindolymaleimide-I) blocked the phosphorylation of ERK1/2 and activation of PKC induced by 12-LOX.	bim	18-21	proline rich transmembrane protein 2	Homo sapiens	101-104
17522976-8	2008	The PKC inhibitor BIM (bisindolymaleimide-I) blocked the phosphorylation of ERK1/2 and activation of PKC induced by 12-LOX.	bim	18-21	arachidonate 15-lipoxygenase	Homo sapiens	116-122
17522976-9	2008	When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only.	bim	21-24	mitogen-activated protein kinase 3	Homo sapiens	55-61
17522976-9	2008	When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only.	bim	21-24	BCL2 apoptosis regulator	Homo sapiens	65-70
17522976-9	2008	When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only.	bim	78-81	mitogen-activated protein kinase 3	Homo sapiens	55-61
17522976-9	2008	When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only.	bim	78-81	BCL2 apoptosis regulator	Homo sapiens	65-70
17522976-9	2008	When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only.	bim	78-81	mitogen-activated protein kinase 3	Homo sapiens	55-61
17522976-9	2008	When pretreated with BIM, the concentration of phospho-ERK1/2 or bcl-2 in the BIM + 12-HETE-treated group was significantly (P < 0.05) lower than in that treated with 12-HETE only, and the concentration in the BIM + baicalein-treated group was significantly (P < 0.05) higher than in that treated with baicalein only.	bim	78-81	BCL2 apoptosis regulator	Homo sapiens	65-70
18245228-7	2008	Incubating MSLN-expressing MDA-MB-231 cells in the presence of U0126, an inhibitor of mitogen-activated protein/extracellular-signal-regulated kinase kinase, induced accumulation of Bim and restored susceptibility to anoikis.	bim	182-185	mesothelin	Homo sapiens	11-15
18046413-6	2007	Analysis of mice deficient in both Bim (which is required for negative selection) and calcineurin revealed that calcineurin-induced ERK (extracellular signal-regulated kinase) sensitization is required for differentiation in response to "weak" positive selecting signals but not in response to "strong" negative selecting signals (which normally induce apoptosis).	bim	35-38	mitogen-activated protein kinase 1	Mus musculus	137-174
17927446-5	2007	The process requires induction of the proapoptotic BH3-only BCL2 family member BIM (i.e., BCL2-like 11, or BCL2L11); erlotinib dramatically induces BIM levels in sensitive but not in resistant cell lines, and knockdown of BIM expression by RNA interference virtually eliminates drug-induced cell killing in vitro.	bim	79-82	BCL2 apoptosis regulator	Homo sapiens	60-64
17698840-5	2007	In addition, TRAIL caused increased binding of Bim and Puma to Mcl-1 that was inhibited by IETD(OMe)-fmk but not SP600125.	bim	47-50	TNF superfamily member 10	Homo sapiens	13-18
17698840-5	2007	In addition, TRAIL caused increased binding of Bim and Puma to Mcl-1 that was inhibited by IETD(OMe)-fmk but not SP600125.	bim	47-50	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	63-68
17698840-7	2007	Collectively, these observations not only suggest a model in which Mcl-1 confers TRAIL resistance by serving as a buffer for Bak, Bim, and Puma, but also identify sorafenib as a potential modulator of TRAIL sensitivity.	bim	130-133	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	67-72
17927446-5	2007	The process requires induction of the proapoptotic BH3-only BCL2 family member BIM (i.e., BCL2-like 11, or BCL2L11); erlotinib dramatically induces BIM levels in sensitive but not in resistant cell lines, and knockdown of BIM expression by RNA interference virtually eliminates drug-induced cell killing in vitro.	bim	79-82	BCL2 like 11	Homo sapiens	90-102
17927446-5	2007	The process requires induction of the proapoptotic BH3-only BCL2 family member BIM (i.e., BCL2-like 11, or BCL2L11); erlotinib dramatically induces BIM levels in sensitive but not in resistant cell lines, and knockdown of BIM expression by RNA interference virtually eliminates drug-induced cell killing in vitro.	bim	79-82	BCL2 like 11	Homo sapiens	107-114
17927446-7	2007	Consistent with these findings, lung tumors and xenografts from mice bearing mutant EGFR-dependent lung adenocarcinomas display increased concentrations of Bim after erlotinib treatment.	bim	156-159	epidermal growth factor receptor	Mus musculus	84-88
17953621-10	2007	Acyl-ghrelin or BIM-28131, a potent ghrelin analog, dose-dependently stimulated food intake by increasing meal size (ghrelin, BIM-28131) and meal number (BIM-28131), while slowing the average eating rate (BIM-28131) similarly in WT and KO mice.	bim	126-129	ghrelin	Mus musculus	5-12
17953621-10	2007	Acyl-ghrelin or BIM-28131, a potent ghrelin analog, dose-dependently stimulated food intake by increasing meal size (ghrelin, BIM-28131) and meal number (BIM-28131), while slowing the average eating rate (BIM-28131) similarly in WT and KO mice.	bim	126-129	ghrelin	Mus musculus	5-12
17540843-1	2007	The role of Bim in synergistic interactions between UCN-01 and MEK1/2 inhibitors in human multiple myeloma cells was investigated.	bim	12-15	urocortin	Homo sapiens	52-55
17540843-1	2007	The role of Bim in synergistic interactions between UCN-01 and MEK1/2 inhibitors in human multiple myeloma cells was investigated.	bim	12-15	mitogen-activated protein kinase kinase 1	Homo sapiens	63-69
17278128-6	2007	The dorsal (DCIC) and external cortices (ECIC) of the IC ipsilateral to the BIM-injected cortex showed a significantly higher number of Fos-labeled neurons than the contralateral IC.	bim	76-79	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	136-139
17384682-7	2007	Stable transfection of esophageal cancer cells with RUNX3 slightly inhibited cell proliferation in vitro, enhanced the antiproliferative and apoptotic effects of TGF-beta and increased radiosensitivity in conjunction with Bim induction.	bim	222-225	RUNX family transcription factor 3	Homo sapiens	52-57
17545623-13	2007	Thus, in myeloma cells, the mechanistic basis for bortezomib sensitivity can be explained mainly by the model in which the sensitizer Noxa can displace Bim, a BH3-only activator, from Mcl-1, thus leading to Bax/Bak activation.	bim	152-155	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	134-138
17545623-13	2007	Thus, in myeloma cells, the mechanistic basis for bortezomib sensitivity can be explained mainly by the model in which the sensitizer Noxa can displace Bim, a BH3-only activator, from Mcl-1, thus leading to Bax/Bak activation.	bim	152-155	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	184-189
17545623-13	2007	Thus, in myeloma cells, the mechanistic basis for bortezomib sensitivity can be explained mainly by the model in which the sensitizer Noxa can displace Bim, a BH3-only activator, from Mcl-1, thus leading to Bax/Bak activation.	bim	152-155	BCL2 associated X, apoptosis regulator	Homo sapiens	207-210
17545623-13	2007	Thus, in myeloma cells, the mechanistic basis for bortezomib sensitivity can be explained mainly by the model in which the sensitizer Noxa can displace Bim, a BH3-only activator, from Mcl-1, thus leading to Bax/Bak activation.	bim	152-155	BCL2 antagonist/killer 1	Homo sapiens	211-214
17374744-4	2007	Inhibition by PKC is blocked by the PKC inhibitors bisindolylmaleimide 1 hydrochloride (BIM) and 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole (Go6976).	bim	88-91	proline rich transmembrane protein 2	Homo sapiens	14-17
17374744-4	2007	Inhibition by PKC is blocked by the PKC inhibitors bisindolylmaleimide 1 hydrochloride (BIM) and 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole (Go6976).	bim	88-91	proline rich transmembrane protein 2	Homo sapiens	36-39
17047391-8	2006	In 19% of the tumors, the maximal inhibition of GH release was achieved with the sst5 preferential compound BIM-23268.	bim	108-111	growth hormone 1	Homo sapiens	48-50
17200126-8	2007	Knockdown of Bim and Bak, downstream targets of Mcl-1, inhibited cycloheximide-induced apoptosis, as did knockdown of Bax.	bim	13-16	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	48-53
17151701-11	2007	BIM(EL) phosphorylation through the ERK pathway targets the protein for proteasomal degradation.	bim	0-3	mitogen-activated protein kinase 1	Homo sapiens	36-39
17200714-6	2007	ABT-737 displaced BIM from BCL2"s BH3-binding pocket, allowing BIM to activate BAX, induce mitochondrial permeabilization, and rapidly commit the CLL cell to death.	bim	18-21	BCL2 apoptosis regulator	Homo sapiens	27-31
16818494-8	2006	Furthermore, sodium arsenite induced Bim(EL) phosphorylation at Ser-65, which was blocked by p38 inhibition.	bim	37-40	mitogen activated protein kinase 14	Rattus norvegicus	93-96
16516835-8	2006	Bim depletion substantially blocks apoptosis and significantly restores Shp2 null TS cell proliferation, thereby establishing a key mechanism by which FGF4 controls stem cell survival.	bim	0-3	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	72-76
16516835-8	2006	Bim depletion substantially blocks apoptosis and significantly restores Shp2 null TS cell proliferation, thereby establishing a key mechanism by which FGF4 controls stem cell survival.	bim	0-3	fibroblast growth factor 4	Mus musculus	151-155
16982767-5	2006	Exposure of cancer cells to BIM-46174 leads to caspase-3-dependent apoptosis and poly(ADP-ribose) polymerase cleavage.	bim	28-31	caspase 3	Homo sapiens	47-56
16982767-5	2006	Exposure of cancer cells to BIM-46174 leads to caspase-3-dependent apoptosis and poly(ADP-ribose) polymerase cleavage.	bim	28-31	poly(ADP-ribose) polymerase 1	Homo sapiens	81-108
16601140-6	2006	Moreover, treatment with both SRIH and BIM-23120 decreases cyclin D1 levels, with a parallel increase in phosphocyclin D1 levels, suggesting protein degradation.	bim	39-42	cyclin D1	Homo sapiens	59-68
16513620-11	2006	Unexpectedly, however, potent sst5 agonists such as KE108, BIM-23244, and L-817,818 were not able to induce sst5 internalization under the same conditions.	bim	59-62	somatostatin receptor 5	Homo sapiens	30-34
16133120-6	2005	Co-incubation of IGF-1 (30 ng/ml) with genistein (25 microM) or BIM (0.5 or 2 microM), lowered of tyrosine kinase receptor or of PKC respectively, inhibited the induced IGF-1 lactotrophs proliferation.	bim	64-67	insulin-like growth factor 1	Rattus norvegicus	17-22
16216913-5	2005	GH secretion was inhibited by BIM-23120 in all samples, while it was reduced by BIM-23206 only in adenomas not expressing DR2.	bim	30-33	growth hormone 1	Homo sapiens	0-2
16216913-8	2005	BIM-23244 reduced PRL secretion only in adenomas expressing sst2, sst5 and DR2.	bim	0-3	prolactin	Homo sapiens	18-21
16133120-6	2005	Co-incubation of IGF-1 (30 ng/ml) with genistein (25 microM) or BIM (0.5 or 2 microM), lowered of tyrosine kinase receptor or of PKC respectively, inhibited the induced IGF-1 lactotrophs proliferation.	bim	64-67	protein kinase C, alpha	Rattus norvegicus	129-132
16133120-6	2005	Co-incubation of IGF-1 (30 ng/ml) with genistein (25 microM) or BIM (0.5 or 2 microM), lowered of tyrosine kinase receptor or of PKC respectively, inhibited the induced IGF-1 lactotrophs proliferation.	bim	64-67	insulin-like growth factor 1	Rattus norvegicus	169-174
15582718-9	2005	Although BIM-23627 itself tended to increase insulin concentration in saline-treated rats, its administration to DEX-treated rats reduced insulin levels (saline: 25+/-3; DEX: 55+/-16*; DEX+BIM-23627: 34+/-5; BIM-23627: 38+/-7 microIU/ml; *P<0.05 vs. saline), apparently improving the degree of insulin sensitivity.	bim	9-12	insulin	Homo sapiens	45-52
15899854-5	2005	Suppression of endogenous Bim greatly inhibits Gadd45a induction of apoptosis.	bim	26-29	growth arrest and DNA damage inducible alpha	Homo sapiens	47-54
15486085-4	2004	IL-3, a hematopoietic survival factor, induces extracellular signal-regulated kinase/mitogen-activated protein kinase-mediated phosphorylation of BIM on three serine sites (S55, S65, and S100).	bim	146-149	interleukin 3	Homo sapiens	0-4
16625841-3	2005	The SSTR2-selective analog, BIM-23197, the SSTR5-selective analog, BIM-23268, and the dopamine (DA) analog, BIM-53097, produced a mean maximal suppression of GH secretion (24 +/- 3, 20 +/- 3, and 20 +/- 3%, respectively) that was similar to that obtained with octreotide (23 +/- 3%).	bim	28-31	somatostatin receptor 2	Homo sapiens	4-9
16625841-3	2005	The SSTR2-selective analog, BIM-23197, the SSTR5-selective analog, BIM-23268, and the dopamine (DA) analog, BIM-53097, produced a mean maximal suppression of GH secretion (24 +/- 3, 20 +/- 3, and 20 +/- 3%, respectively) that was similar to that obtained with octreotide (23 +/- 3%).	bim	67-70	somatostatin receptor 2	Homo sapiens	4-9
16625841-3	2005	The SSTR2-selective analog, BIM-23197, the SSTR5-selective analog, BIM-23268, and the dopamine (DA) analog, BIM-53097, produced a mean maximal suppression of GH secretion (24 +/- 3, 20 +/- 3, and 20 +/- 3%, respectively) that was similar to that obtained with octreotide (23 +/- 3%).	bim	67-70	somatostatin receptor 5	Homo sapiens	43-48
16625841-3	2005	The SSTR2-selective analog, BIM-23197, the SSTR5-selective analog, BIM-23268, and the dopamine (DA) analog, BIM-53097, produced a mean maximal suppression of GH secretion (24 +/- 3, 20 +/- 3, and 20 +/- 3%, respectively) that was similar to that obtained with octreotide (23 +/- 3%).	bim	67-70	somatostatin receptor 2	Homo sapiens	4-9
16625841-3	2005	The SSTR2-selective analog, BIM-23197, the SSTR5-selective analog, BIM-23268, and the dopamine (DA) analog, BIM-53097, produced a mean maximal suppression of GH secretion (24 +/- 3, 20 +/- 3, and 20 +/- 3%, respectively) that was similar to that obtained with octreotide (23 +/- 3%).	bim	67-70	somatostatin receptor 5	Homo sapiens	43-48
16625841-10	2005	After a brief exposure to a SSTR2-selective analog, BIM-23197, or to a DA analog, BIM-53097, the maximal GH suppression was achieved during 12 h. Under exposure to BIM-23A760, in the same conditions, maximal suppression of GH secretion lasted for 24 h. Such a longer biological effect, yet not explained, probably participates in the higher efficacy of BIM-23A760.	bim	52-55	somatostatin receptor 2	Homo sapiens	28-33
16210868-6	2005	In keeping with our results on growth hormone (GH) secretion, BIM-28163 acts as an antagonist of ghrelin-induced Fos protein immunoreactivity (Fos-IR) in the medial arcuate nucleus, an area involved in the ghrelin modulation of GH secretion.	bim	62-65	growth hormone 1	Homo sapiens	31-45
16210868-6	2005	In keeping with our results on growth hormone (GH) secretion, BIM-28163 acts as an antagonist of ghrelin-induced Fos protein immunoreactivity (Fos-IR) in the medial arcuate nucleus, an area involved in the ghrelin modulation of GH secretion.	bim	62-65	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	113-116
16210868-6	2005	In keeping with our results on growth hormone (GH) secretion, BIM-28163 acts as an antagonist of ghrelin-induced Fos protein immunoreactivity (Fos-IR) in the medial arcuate nucleus, an area involved in the ghrelin modulation of GH secretion.	bim	62-65	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	143-146
16210868-8	2005	The observation that ghrelin and BIM-28163 have different efficacies in inducing Fos-IR in the DMH, and that concomitant administration of ghrelin and an excess of BIM-28163 results in the same level of Fos-IR as BIM-28163 administered alone may demonstrate that in the DMH both ghrelin and BIM-28163 act via the same receptor.	bim	164-167	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	203-206
16210868-8	2005	The observation that ghrelin and BIM-28163 have different efficacies in inducing Fos-IR in the DMH, and that concomitant administration of ghrelin and an excess of BIM-28163 results in the same level of Fos-IR as BIM-28163 administered alone may demonstrate that in the DMH both ghrelin and BIM-28163 act via the same receptor.	bim	164-167	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	203-206
16210868-8	2005	The observation that ghrelin and BIM-28163 have different efficacies in inducing Fos-IR in the DMH, and that concomitant administration of ghrelin and an excess of BIM-28163 results in the same level of Fos-IR as BIM-28163 administered alone may demonstrate that in the DMH both ghrelin and BIM-28163 act via the same receptor.	bim	164-167	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	203-206
15138279-2	2004	However, the exact mechanism by which tBID and BIM(EL) aid BAX and its close homologues in this mitochondrial protein release remains enigmatic.	bim	47-50	BCL2 associated X, apoptosis regulator	Homo sapiens	59-62
15378010-0	2004	Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis.	bim	65-68	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	12-17
15265812-8	2004	The actions of somatostatin in brain slices were mimicked by BIM-23027, but not by CH-275.	bim	61-64	somatostatin	Rattus norvegicus	15-27
15356200-0	2004	The c-Jun N-terminal protein kinase signaling pathway mediates Bax activation and subsequent neuronal apoptosis through interaction with Bim after transient focal cerebral ischemia.	bim	137-140	mitogen-activated protein kinase 8	Homo sapiens	4-35
15356200-0	2004	The c-Jun N-terminal protein kinase signaling pathway mediates Bax activation and subsequent neuronal apoptosis through interaction with Bim after transient focal cerebral ischemia.	bim	137-140	BCL2 associated X, apoptosis regulator	Homo sapiens	63-66
15339248-4	2004	In vivo, BIM-28163 does not increase GH secretion but fully blocks ghrelin-induced GH secretion.	bim	9-12	ghrelin and obestatin prepropeptide	Rattus norvegicus	67-74
15339248-5	2004	In contrast, BIM-28163 acts as a full agonist with regard to the ghrelin actions of stimulating weight gain and food intake.	bim	13-16	ghrelin and obestatin prepropeptide	Rattus norvegicus	65-72
15079075-0	2004	Bim is a suppressor of Myc-induced mouse B cell leukemia.	bim	0-3	myelocytomatosis oncogene	Mus musculus	23-26
15079075-3	2004	Bim, a distant proapoptotic relative, is emerging as a major physiologic antagonist of Bcl2.	bim	0-3	B cell leukemia/lymphoma 2	Mus musculus	87-91
15103227-3	2004	In addition, the inhibiting effect of BIM-23745 on the GH secretion was compared with that of octreotide.	bim	38-41	growth hormone 1	Homo sapiens	55-57
15017595-9	2004	CD10-positive brush border was present in 32.3%/25.8% of BIM and in 88.9%/88.9% of CIM.	bim	57-60	membrane metalloendopeptidase	Homo sapiens	0-4
15017595-13	2004	CD10-positive intestinal brush border is present in the majority of CIM but only in a minority of BIM.	bim	98-101	membrane metalloendopeptidase	Homo sapiens	0-4
15456957-5	2004	Forskolin-induced cAMP accumulation and chromogranin A (CgA) secretion were inhibited by BIM-23120, BIM-23206, and somatostatin-14 in a dose-dependent manner.	bim	89-92	chromogranin A	Homo sapiens	40-54
15456957-5	2004	Forskolin-induced cAMP accumulation and chromogranin A (CgA) secretion were inhibited by BIM-23120, BIM-23206, and somatostatin-14 in a dose-dependent manner.	bim	89-92	chromogranin A	Homo sapiens	56-59
15456957-5	2004	Forskolin-induced cAMP accumulation and chromogranin A (CgA) secretion were inhibited by BIM-23120, BIM-23206, and somatostatin-14 in a dose-dependent manner.	bim	100-103	chromogranin A	Homo sapiens	40-54
15456957-5	2004	Forskolin-induced cAMP accumulation and chromogranin A (CgA) secretion were inhibited by BIM-23120, BIM-23206, and somatostatin-14 in a dose-dependent manner.	bim	100-103	chromogranin A	Homo sapiens	56-59
12970293-8	2003	The IC(50) for BIM-23454 reversal of agonist-induced GH suppression was 55 nM and 33 nM for two SSTR2 agonists, 45 nM and 40 nM for the combination of SSTR2 and SSTR5 agonists, respectively, and 45 nM for the SSTR2/SSTR5 agonist BIM-23244, all of which were similar to the affinity of BIM-23454 for SSTR2 (32 nM).	bim	15-18	somatostatin receptor 2	Homo sapiens	96-101
14602782-2	2003	The selective SSTR2 agonist, BIM-23023 (50% effective dose, 0.42), and the DAR2 agonist, BIM-53097 (50% effective dose, 22.1), dose- dependently inhibited GH secretion in cultured primary rat and human fetal as well as in human pituitary tumor cells derived from GH-secreting adenomas.	bim	29-32	somatostatin receptor 2	Rattus norvegicus	14-19
14511121-8	2003	The induction by CNTF was inhibited by the protein kinase C inhibitor, BIM, and the MAPK-kinase inhibitor, U0126.	bim	71-74	ciliary neurotrophic factor	Homo sapiens	17-21
12970293-8	2003	The IC(50) for BIM-23454 reversal of agonist-induced GH suppression was 55 nM and 33 nM for two SSTR2 agonists, 45 nM and 40 nM for the combination of SSTR2 and SSTR5 agonists, respectively, and 45 nM for the SSTR2/SSTR5 agonist BIM-23244, all of which were similar to the affinity of BIM-23454 for SSTR2 (32 nM).	bim	15-18	somatostatin receptor 5	Homo sapiens	161-166
12970293-8	2003	The IC(50) for BIM-23454 reversal of agonist-induced GH suppression was 55 nM and 33 nM for two SSTR2 agonists, 45 nM and 40 nM for the combination of SSTR2 and SSTR5 agonists, respectively, and 45 nM for the SSTR2/SSTR5 agonist BIM-23244, all of which were similar to the affinity of BIM-23454 for SSTR2 (32 nM).	bim	15-18	somatostatin receptor 5	Homo sapiens	215-220
12881569-6	2003	Death signals activate "BH3-only" molecules such as tBID, BIM, or BAD, which displace VDAC2 from BAK, enabling homo-oligomerization of BAK and apoptosis.	bim	58-61	voltage dependent anion channel 2	Homo sapiens	86-91
12881569-6	2003	Death signals activate "BH3-only" molecules such as tBID, BIM, or BAD, which displace VDAC2 from BAK, enabling homo-oligomerization of BAK and apoptosis.	bim	58-61	BCL2 antagonist/killer 1	Homo sapiens	135-138
12881569-6	2003	Death signals activate "BH3-only" molecules such as tBID, BIM, or BAD, which displace VDAC2 from BAK, enabling homo-oligomerization of BAK and apoptosis.	bim	58-61	BCL2 antagonist/killer 1	Homo sapiens	97-100
12750875-8	2003	The effects of the sst2 receptor-preferring agonists Tyr3-octreotide and BIM 23027 on [35S]GTPgammaS binding, but not those of SRIF-14 and the sst5/1 receptor selective-agonist L-817,818, were competitively antagonised by the sst2 receptor antagonist d-Tyr8-CYN 154806 (pKB=7.36 and 7.72, respectively; slope factors not significantly different from unity).	bim	73-76	somatostatin receptor 2	Mus musculus	19-23
12591950-0	2003	JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis.	bim	23-26	mitogen-activated protein kinase 8	Homo sapiens	0-3
12741473-5	2003	BIM inhibited alpha-smooth muscle actin expression by 60%, but had no significant effect on proliferation.	bim	0-3	actin gamma 2, smooth muscle	Rattus norvegicus	14-39
12591950-0	2003	JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis.	bim	23-26	BCL2 apoptosis regulator	Homo sapiens	50-54
12591950-0	2003	JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis.	bim	23-26	BCL2 associated X, apoptosis regulator	Homo sapiens	70-73
12618753-3	2003	Serum withdrawal promoted the rapid, de novo accumulation of Bim(EL), a proapoptotic "BH3-only" member of the Bcl-2 protein family.	bim	61-64	BCL2 apoptosis regulator	Homo sapiens	110-115
12466351-0	2002	Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.	bim	80-83	growth hormone 1	Homo sapiens	107-121
12466351-0	2002	Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.	bim	80-83	prolactin	Homo sapiens	126-135
11566490-6	2001	[D-Phe(6)]bombesin-(6-13)methyl ester (A1) and BIM-23127 (A2), are considered as inhibitors of binding to GRP-R and NMB-R, respectively.	bim	47-50	gastrin releasing peptide receptor	Homo sapiens	106-111
11709185-0	2001	Degenerative disorders caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim.	bim	95-98	B cell leukemia/lymphoma 2	Mus musculus	33-38
11897676-0	2002	Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454.	bim	100-103	somatostatin receptor 2	Rattus norvegicus	34-65
11566490-6	2001	[D-Phe(6)]bombesin-(6-13)methyl ester (A1) and BIM-23127 (A2), are considered as inhibitors of binding to GRP-R and NMB-R, respectively.	bim	47-50	neuromedin B receptor	Homo sapiens	116-121
11415850-11	2001	The SSTR2 (BIM-23197, lanreotide) and SSTR5 (BIM-23268) preferential analogues both produced a partial 21-38% inhibition of PRL, LH, and alpha-subunit release.	bim	11-14	somatostatin receptor 2	Homo sapiens	4-9
11732266-0	2001	[Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma].	bim	85-88	somatostatin	Homo sapiens	49-61
8938650-1	1996	We have previously shown that the somatostatin (SRIF) sst2 receptor-selective peptide, BIM-23027, is a potent antisecretory agent in rat isolated distal colonic mucosa (RDCM) and in radioligand binding studies in RDCM membranes, it only maximally inhibited approximately 40% of [125I]-Tyr11-SRIF-14 binding (McKeen ES, Feniuk W, Humphrey PPA (1995) Naunyn-Schmiedeberg"s Arch Pharmacol 352:402-411).	bim	87-90	somatostatin	Mus musculus	48-52
11231991-7	2001	In these tumors the suppression of GH release was similarly achieved at picomolar ranges by octreotide, BIM-23197, and BIM-23244 (EC(50) = 25 +/- 15, 3 +/- 2, and 3 +/- 3 pmol/L, respectively).	bim	104-107	growth hormone 1	Homo sapiens	35-37
11231991-7	2001	In these tumors the suppression of GH release was similarly achieved at picomolar ranges by octreotide, BIM-23197, and BIM-23244 (EC(50) = 25 +/- 15, 3 +/- 2, and 3 +/- 3 pmol/L, respectively).	bim	119-122	growth hormone 1	Homo sapiens	35-37
11231991-11	2001	Similarly, BIM-23244, was able to suppress by 51 +/- 5% PRL release from five mixed GH- and PRL-secreting adenomas.	bim	11-14	growth hormone 1	Homo sapiens	84-86
11052995-4	2000	PYY was inhibited by two analogs with affinity for SSTR-5, BIM-23268 and BIM-23052, more potently than S-14 and as effectively as S-28.	bim	59-62	peptide YY	Rattus norvegicus	0-3
11052995-4	2000	PYY was inhibited by two analogs with affinity for SSTR-5, BIM-23268 and BIM-23052, more potently than S-14 and as effectively as S-28.	bim	59-62	somatostatin receptor 5	Rattus norvegicus	51-57
10487698-3	1999	The present study examines the quantitative profile of SSTRs messenger ribonucleic acid (mRNA) in 10 PRL-secreting tumors and correlates the expression with the ability of native somatostatins (SS14 and SS28), SSTR2 preferential analogs (octreotide and BIM-23197), and the SSTR5 preferential analog BIM-23268 to suppress PRL secretion.	bim	253-256	somatostatin receptor 2	Homo sapiens	210-215
10408834-8	1999	On the contrary, an inhibitor of protein kinase C (bis-indolyl-maleimide, BIM) was effective only in the FMLP/Lym-1 cytolytic system.	bim	74-77	formyl peptide receptor 1	Homo sapiens	105-109
10080163-6	1999	The novel PYY analogs, BIM-43073D and BIM-43004C, are effective proabsorptive agents with BIM-43073D producing more sustained effects than PYY.	bim	23-26	peptide YY	Canis lupus familiaris	10-13
10080163-6	1999	The novel PYY analogs, BIM-43073D and BIM-43004C, are effective proabsorptive agents with BIM-43073D producing more sustained effects than PYY.	bim	23-26	peptide YY	Canis lupus familiaris	139-142
10080163-6	1999	The novel PYY analogs, BIM-43073D and BIM-43004C, are effective proabsorptive agents with BIM-43073D producing more sustained effects than PYY.	bim	38-41	peptide YY	Canis lupus familiaris	10-13
9227485-6	1997	Only the highest doses (5 nmol.kg-1.h-1) of BIM-23058 and BIM-23052 significantly inhibited gastrin release and acid secretion.	bim	44-47	gastrin	Canis lupus familiaris	92-99
9227485-6	1997	Only the highest doses (5 nmol.kg-1.h-1) of BIM-23058 and BIM-23052 significantly inhibited gastrin release and acid secretion.	bim	58-61	gastrin	Canis lupus familiaris	92-99
10690891-3	2000	In the present study the quantitative expression of messenger ribonucleic acid (mRNA) for the 5 SSTR subtypes and the inhibitory effects of SRIF14; SRIF28; octreotide; the SSTR2-preferential analog, BIM-23197; and the SSTR5-preferential analog, BIM-23268, on GH and PRL secretion were analyzed in cells cultured from 15 acromegalic tumors.	bim	199-202	somatostatin receptor 2	Homo sapiens	172-177
10690891-10	2000	In contrast, the SSTR2-preferential analogs, BIM-23197 and octreotide, were effective in suppressing PRL in only 6 of 10 cases.	bim	45-48	somatostatin receptor 2	Homo sapiens	17-22
11268382-0	2000	The role of bim, a proapoptotic BH3-only member of the Bcl-2 family in cell-death control.	bim	12-15	B cell leukemia/lymphoma 2	Mus musculus	55-60
9117097-3	1997	The potent SRIF1-receptor selective ligand, BIM-23027, was able to displace completely the specific binding of radioiodinated somatostatin, [125I]-Tyr11-SRIF-14, with a pIC50 of 10.3, suggesting that Neuro2A cells contain predominantly receptors of the SRIF1 receptor group.	bim	44-47	somatostatin receptor 2	Mus musculus	11-16
9117097-3	1997	The potent SRIF1-receptor selective ligand, BIM-23027, was able to displace completely the specific binding of radioiodinated somatostatin, [125I]-Tyr11-SRIF-14, with a pIC50 of 10.3, suggesting that Neuro2A cells contain predominantly receptors of the SRIF1 receptor group.	bim	44-47	somatostatin	Mus musculus	11-15
9117097-3	1997	The potent SRIF1-receptor selective ligand, BIM-23027, was able to displace completely the specific binding of radioiodinated somatostatin, [125I]-Tyr11-SRIF-14, with a pIC50 of 10.3, suggesting that Neuro2A cells contain predominantly receptors of the SRIF1 receptor group.	bim	44-47	somatostatin receptor 2	Mus musculus	253-258
8938650-1	1996	We have previously shown that the somatostatin (SRIF) sst2 receptor-selective peptide, BIM-23027, is a potent antisecretory agent in rat isolated distal colonic mucosa (RDCM) and in radioligand binding studies in RDCM membranes, it only maximally inhibited approximately 40% of [125I]-Tyr11-SRIF-14 binding (McKeen ES, Feniuk W, Humphrey PPA (1995) Naunyn-Schmiedeberg"s Arch Pharmacol 352:402-411).	bim	87-90	somatostatin receptor 2	Mus musculus	54-58
8938650-1	1996	We have previously shown that the somatostatin (SRIF) sst2 receptor-selective peptide, BIM-23027, is a potent antisecretory agent in rat isolated distal colonic mucosa (RDCM) and in radioligand binding studies in RDCM membranes, it only maximally inhibited approximately 40% of [125I]-Tyr11-SRIF-14 binding (McKeen ES, Feniuk W, Humphrey PPA (1995) Naunyn-Schmiedeberg"s Arch Pharmacol 352:402-411).	bim	87-90	somatostatin	Mus musculus	291-295
8938650-11	1996	[125I]-BIM-23027 labelled a single population of SRIF binding sites in RDCM membranes and mouse fibroblast (Ltk-) cells stably expressing the human recombinant sst2 receptor.	bim	7-10	somatostatin	Mus musculus	49-53
8938650-11	1996	[125I]-BIM-23027 labelled a single population of SRIF binding sites in RDCM membranes and mouse fibroblast (Ltk-) cells stably expressing the human recombinant sst2 receptor.	bim	7-10	somatostatin receptor 2	Mus musculus	160-164
8938650-12	1996	There was a significant correlation between the affinity estimates of a range of SRIF analogues at inhibiting [125I]-BIM-23027 binding in RDCM membranes and binding to the recombinant sst2 receptor in Ltk- cells, suggesting that the sites labelled by [125I]-BIM-23027 in RDCM are similar to the sst2 receptor.	bim	117-120	somatostatin	Mus musculus	81-85
8938650-12	1996	There was a significant correlation between the affinity estimates of a range of SRIF analogues at inhibiting [125I]-BIM-23027 binding in RDCM membranes and binding to the recombinant sst2 receptor in Ltk- cells, suggesting that the sites labelled by [125I]-BIM-23027 in RDCM are similar to the sst2 receptor.	bim	258-261	somatostatin	Mus musculus	81-85
8786559-4	1996	GRP-induced secretion was antagonized by three bombesin-like peptide analogs: BIM-26028, BIM-26187 and BIM-26226.	bim	89-92	gastrin releasing peptide	Homo sapiens	47-55
8786559-5	1996	Total protein secretion induced by 100 nM GRP was reduced 50% by BIM-compounds at concentrations of 1 to 3 nM, although BIM-26226 was even more potent on alkaline phosphatase secretion.	bim	65-68	gastrin-releasing peptide	Cavia porcellus	42-45
8786559-4	1996	GRP-induced secretion was antagonized by three bombesin-like peptide analogs: BIM-26028, BIM-26187 and BIM-26226.	bim	78-81	gastrin-releasing peptide	Cavia porcellus	0-3
8786559-4	1996	GRP-induced secretion was antagonized by three bombesin-like peptide analogs: BIM-26028, BIM-26187 and BIM-26226.	bim	78-81	gastrin releasing peptide	Homo sapiens	47-55
8786559-4	1996	GRP-induced secretion was antagonized by three bombesin-like peptide analogs: BIM-26028, BIM-26187 and BIM-26226.	bim	89-92	gastrin-releasing peptide	Cavia porcellus	0-3
8786559-4	1996	GRP-induced secretion was antagonized by three bombesin-like peptide analogs: BIM-26028, BIM-26187 and BIM-26226.	bim	89-92	gastrin releasing peptide	Homo sapiens	47-55
8786559-4	1996	GRP-induced secretion was antagonized by three bombesin-like peptide analogs: BIM-26028, BIM-26187 and BIM-26226.	bim	89-92	gastrin-releasing peptide	Cavia porcellus	0-3
8596194-6	1995	The selective inhibitor of protein kinase C (PKC), bisindolylmalemide (BIM) (5 microM), reduced significantly the incorporation of l-[14C] phenylalanine into cellular protein in response to phenylephrine (1 microM), employed as a positive control, but did not inhibit the response to insulin (1 unit/ml), employed as a negative control.	bim	71-74	proline rich transmembrane protein 2	Homo sapiens	27-43
8596194-6	1995	The selective inhibitor of protein kinase C (PKC), bisindolylmalemide (BIM) (5 microM), reduced significantly the incorporation of l-[14C] phenylalanine into cellular protein in response to phenylephrine (1 microM), employed as a positive control, but did not inhibit the response to insulin (1 unit/ml), employed as a negative control.	bim	71-74	proline rich transmembrane protein 2	Homo sapiens	45-48
8596194-7	1995	BIM (5 microM) reduced significantly the responses to FCS (10% v/v), amylin (10 nM) and CGRP (10 pM), but did not inhibit the response to CGRP (100 pM).	bim	0-3	islet amyloid polypeptide	Homo sapiens	69-75
8596194-7	1995	BIM (5 microM) reduced significantly the responses to FCS (10% v/v), amylin (10 nM) and CGRP (10 pM), but did not inhibit the response to CGRP (100 pM).	bim	0-3	calcitonin related polypeptide alpha	Homo sapiens	88-92
7669056-3	1995	The SSTR3 and SSTR5-selective ligands, BIM-23056 and BIM-23052, were inactive and weakly active, respectively.	bim	39-42	somatostatin receptor 3	Rattus norvegicus	4-9
7669056-3	1995	The SSTR3 and SSTR5-selective ligands, BIM-23056 and BIM-23052, were inactive and weakly active, respectively.	bim	39-42	somatostatin receptor 5	Rattus norvegicus	14-19
7707868-5	1995	The specific inhibitor of the PKC bisindolymaleimide (BIM) abolished the upregulation of the VEGF mRNA by adenosine completely.	bim	54-57	PKC	Sus scrofa	30-33
7579488-0	1995	Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer.	bim	50-53	somatostatin	Homo sapiens	64-76
7630141-0	1995	A novel synthetic analog of peptide YY, BIM-43004, given intraluminally, is proabsorptive.	bim	40-43	peptide YY	Homo sapiens	28-38
7707868-5	1995	The specific inhibitor of the PKC bisindolymaleimide (BIM) abolished the upregulation of the VEGF mRNA by adenosine completely.	bim	54-57	vascular endothelial growth factor A	Sus scrofa	93-97
7587647-9	1995	We then expressed sstr2A in monkey kidney COS-7 cells and mouse NIH/3T3 fibroblasts and demonstrated that somatostatin analogues (RC 160, octreotide and BIM 23014) which exhibited high affinity for sstr2 stimulated a PTP activity and inhibited cell proliferation in proportion to their affinities for sstr2.	bim	153-156	somatostatin receptor 2	Mus musculus	18-23
7587647-9	1995	We then expressed sstr2A in monkey kidney COS-7 cells and mouse NIH/3T3 fibroblasts and demonstrated that somatostatin analogues (RC 160, octreotide and BIM 23014) which exhibited high affinity for sstr2 stimulated a PTP activity and inhibited cell proliferation in proportion to their affinities for sstr2.	bim	153-156	protein tyrosine phosphatase, receptor type, S	Mus musculus	217-220
7587647-9	1995	We then expressed sstr2A in monkey kidney COS-7 cells and mouse NIH/3T3 fibroblasts and demonstrated that somatostatin analogues (RC 160, octreotide and BIM 23014) which exhibited high affinity for sstr2 stimulated a PTP activity and inhibited cell proliferation in proportion to their affinities for sstr2.	bim	153-156	somatostatin receptor 2	Mus musculus	198-203
2160386-5	1990	Administration of a GnRH antagonist (BIM 21009, 1 mg/kg/24 h) induced a rapid reduction of pituitary and testicular receptors to undetectable levels at 24 h, while hippocampal receptors were strongly reduced only.	bim	37-40	gonadotropin releasing hormone 1	Rattus norvegicus	20-24
1674613-0	1991	Immunomodulatory activities of the somatostatin analogue BIM 23014c: effects on murine lymphocyte proliferation and natural killer activity.	bim	57-60	somatostatin	Mus musculus	35-47
8405033-2	1993	BIM 250 micrograms sc significantly reduced a GHRH-induced increase in plasma GH.	bim	0-3	growth hormone releasing hormone	Homo sapiens	46-50
8405033-8	1993	We conclude that BIM 23,014 250 to 1000 micrograms sc is able to reduce the plasma GH response to GHRH or to the fall in glucose following an oral glucose tolerance test; a constant infusion of BIM, in doses 1000 micrograms daily, dramatically suppresses spontaneous GH secretion; 2000 micrograms/day by chronic subcutaneous infusion was the most effective dose of BIM in the suppression of GH secretion, and was associated only with minor adverse effects.	bim	17-20	growth hormone releasing hormone	Homo sapiens	98-102
1478250-6	1992	In study 2 BIM infusion induced glucose intolerance and a drop in plasma insulin and C-peptide on day 1 which disappeared on day 7 of infusion.	bim	11-14	insulin	Homo sapiens	73-80
1478250-6	1992	In study 2 BIM infusion induced glucose intolerance and a drop in plasma insulin and C-peptide on day 1 which disappeared on day 7 of infusion.	bim	11-14	insulin	Homo sapiens	85-94
1332139-6	1992	[D-Phe6]Bombesin(6-13)-propylamide (BIM), a member of another class of antagonists, reported previously to be the most potent antagonist, in vitro, on the other hand, enhanced bombesin provoked gastrin release in rats.	bim	36-39	gastrin	Rattus norvegicus	194-201
34312366-8	2021	In the presence of NOXA, BIM-deficient HCC cells could be in turn strongly sensitized for cell death induction by the combination of sorafenib with TRAIL.	bim	25-28	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	19-23
34388376-0	2021	Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis.	bim	107-110	epidermal growth factor receptor	Homo sapiens	63-67
34312366-8	2021	In the presence of NOXA, BIM-deficient HCC cells could be in turn strongly sensitized for cell death induction by the combination of sorafenib with TRAIL.	bim	25-28	TNF superfamily member 10	Homo sapiens	148-153
35328342-4	2022	The combinatory treatment of BI-D1870, an inhibitor for N-terminal kinase domain (NTKD) of RSK2, and ipatasertib, an inhibitor for AKT, showed the additive to synergistic anti-tumor effect on human MM-derived cell lines (HMCLs) with active RSK2-NTKD and AKT, by enhancing apoptotic induction with BIM and BID activation.	bim	297-300	ribosomal protein S6 kinase A3	Homo sapiens	91-95
34322387-11	2021	Conclusion: Downregulation of ATXN3 enhanced AKT inhibitors (perifosine or MK-2206) induced cell death by BIM, but decreased the cell death induced by chemotherapeutic drugs (etoposide or cisplatin) via Bcl-xl.	bim	106-109	ataxin 3	Homo sapiens	30-35
34322387-11	2021	Conclusion: Downregulation of ATXN3 enhanced AKT inhibitors (perifosine or MK-2206) induced cell death by BIM, but decreased the cell death induced by chemotherapeutic drugs (etoposide or cisplatin) via Bcl-xl.	bim	106-109	AKT serine/threonine kinase 1	Homo sapiens	45-48
32161312-7	2020	This promotes the activation of BAK and BAX and caspase-dependent apoptosis, as (1) individual silencing of BMF, BIM, NOXA, BAK, or BAX, (2) overexpression of BCL-2 or MCL-1 or (3) the caspase inhibitor N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone (zVAD.fmk) all rescue JQ1/BYL719-induced cell death.	bim	113-116	BCL2 antagonist/killer 1	Homo sapiens	32-35
2563730-0	1989	Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men.	bim	35-38	growth hormone 1	Homo sapiens	65-79
34024909-0	2021	FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.	bim	115-118	fms related receptor tyrosine kinase 3	Homo sapiens	0-4
34024909-0	2021	FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.	bim	115-118	BCL2 apoptosis regulator	Homo sapiens	47-52
34024909-0	2021	FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.	bim	115-118	fms related receptor tyrosine kinase 3	Homo sapiens	77-81
32428383-1	2020	The 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine derivative BIM-46174 and its dimeric form BIM-46187 (1) are heterocyclized dipeptides that belong to the very few cell-permeable compounds known to preferentially silence Galphaq proteins.	bim	56-59	G protein subunit alpha q	Homo sapiens	216-223
32247610-0	2020	EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-XL inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells.	bim	106-109	zinc finger E-box binding homeobox 1	Homo sapiens	34-38
32247610-0	2020	EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-XL inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells.	bim	106-109	BCL2 apoptosis regulator	Homo sapiens	68-73
32247610-0	2020	EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-XL inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells.	bim	106-109	BCL2 like 1	Homo sapiens	74-80
32291856-9	2020	We found that CH5126766 and R428 suppressed the phosphorylation of ERK and AKT, respectively, and their combination synergistically inhibited the growth of both cell lines with enhancement of apoptosis accompanied by the Bim upregulation.	bim	221-224	mitogen-activated protein kinase 1	Homo sapiens	67-70
32291856-9	2020	We found that CH5126766 and R428 suppressed the phosphorylation of ERK and AKT, respectively, and their combination synergistically inhibited the growth of both cell lines with enhancement of apoptosis accompanied by the Bim upregulation.	bim	221-224	AKT serine/threonine kinase 1	Homo sapiens	75-78
31390099-5	2019	Our results indicate that the tri(azaindolyl)borane-Rh catalyst favors the synergetic heterolytic mechanism; the PBP-Co catalyst prefers the mer(trans)-homolytic mechanism; the DPB-Pd catalyst operates through the fac(cis)-homolytic mechanism, whereas the BIM-Pt catalyst tends to undergo the dissociative heterolytic mechanism.	bim	256-259	pro-platelet basic protein	Homo sapiens	113-116
30846494-7	2019	We identified that while single-agent MEK inhibition increased BIM levels, it remained sequestered by anti-apoptotic BCL-2 family members.	bim	63-66	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
30763060-1	2019	We recently reported that AMP-activated protein kinase (AMPK) contributes to zinc-induced neuronal death by inducing Bim, a pro-apoptotic Bcl-2 homology domain 3-only protein, in a liver kinase B1 (LKB1)-dependent manner.	bim	117-120	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	26-54
30763060-1	2019	We recently reported that AMP-activated protein kinase (AMPK) contributes to zinc-induced neuronal death by inducing Bim, a pro-apoptotic Bcl-2 homology domain 3-only protein, in a liver kinase B1 (LKB1)-dependent manner.	bim	117-120	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	56-60
30763060-1	2019	We recently reported that AMP-activated protein kinase (AMPK) contributes to zinc-induced neuronal death by inducing Bim, a pro-apoptotic Bcl-2 homology domain 3-only protein, in a liver kinase B1 (LKB1)-dependent manner.	bim	117-120	BCL2, apoptosis regulator	Rattus norvegicus	138-143
30763060-1	2019	We recently reported that AMP-activated protein kinase (AMPK) contributes to zinc-induced neuronal death by inducing Bim, a pro-apoptotic Bcl-2 homology domain 3-only protein, in a liver kinase B1 (LKB1)-dependent manner.	bim	117-120	serine/threonine kinase 11	Rattus norvegicus	181-196
30763060-1	2019	We recently reported that AMP-activated protein kinase (AMPK) contributes to zinc-induced neuronal death by inducing Bim, a pro-apoptotic Bcl-2 homology domain 3-only protein, in a liver kinase B1 (LKB1)-dependent manner.	bim	117-120	serine/threonine kinase 11	Rattus norvegicus	198-202
31114224-11	2019	Conclusion: IL-37 upregulated Bim in cervical cancer cells.	bim	30-33	interleukin 37	Homo sapiens	12-17